natgillin/translations-raw huggingface dataset:
CI = confidence interval; NA = not applicable.
IZ = interval zaupanja; NA = ne velja za ta primer.
Antihistamines are given to help prevent an allergic reaction to Torisel, including some lifethreatening and rare fatal allergic reactions.
Antihistaminike se daje, da bi poskusili preprečiti alergijsko reakcijo na zdravilo Torisel, vključno z nekaterimi življenjsko ogrožajočimi in redkimi smrtnimi alergijskimi reakcijami.
Store in a refrigerator (2°C - 8°C)
Shranjujte v hladilniku (2 °C - 8 °C).
If you feel sick (nausea and vomiting) or you have difficulty in falling or staying asleep, take special care when driving or using machines.
Če vam je slabo (navzea in bruhanje) ali če težko zaspite ali se zbujate, bodite posebno pazljivi pri vožnji ali upravljanju strojev.
What you need to know before you receive Torisel 3.
Kaj morate vedeti, preden boste prejeli zdravilo Torisel 3.
The results for the MCL clinical trial are summarised in the following table.
Rezultati kliničnega preskušanja MCL so povzeti v naslednji preglednici.
Women should not breast-feed during treatment with Torisel, as this medicine may interfere with the growth and development of the baby.
Ženske med zdravljenjem z zdravilom Torisel ne smejo dojiti, ker utegne to zdravilo ovirati rast in razvoj otroka.
Frequencies are defined as follows: very common (1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (1/10,000 to <1/1,000), very rare (<1/10,000) and not known (cannot be estimated from the available data).Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Pogostnosti so opredeljene na naslednji način: zelo pogosti ( 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki ( 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Exposures in animals were lower than those seen in humans receiving clinically relevant doses of temsirolimus.
Izpostavljenosti pri živalih so bile manjše od tistih, ki so jih ugotovili pri ljudeh, ki so prejemali klinično pomembne odmerke temsirolimusa.
Abbreviation: ANC = absolute neutrophil count.
Okrajšava: ANC (ANC - Absolute Neutrophil Count) - absolutno število nevtrofilcev
These transcription factors regulate the ability of tumours to adapt to hypoxic microenvironments and to produce the angiogenic factor vascular endothelial growth factor (VEGF).
Ta transkripcijska faktorja regulirata sposobnost tumorjev, da se prilagodijo na hipoksično mikrookolje in da izdelujejo angiogeni faktor z imenom rastni faktor vaskularnega endotelija (VEGF).
Post-marketing experience
Izkušnje v obdobju trženja
In addition to regulating cell cycle proteins, mTOR can regulate translation of the hypoxia-inducible factors, HIF-1 and HIF-2 alpha.
Poleg tega, da uravnava beljakovine celičnega cikla, lahko mTOR uravnava translacijo faktorjev, ki se inducirajo s hipoksijo, to sta HIF-1 in HIF-2 alfa.
Your doctor may prescribe you an x-ray examination of your chest.
Zdravnik vam bo morda naročil, da opravite rentgenski pregled prsnega koša.
• Mix the solvent and the concentrate well by inversion of the vial.
• Dobro zmešajte vehikel in koncentrat z obračanjem viale.
This may increase the risk of bleeding in your body.
To lahko poveča tveganje za krvavitve v vašem telesu.
Adverse reactions that were reported in post-marketing experience are listed below (Table 2).
Neželeni učinki, o katerih so poročali v obdobju trženja, so našteti spodaj (preglednica 2).
Interaction with medicinal products metabolised by CYP2D6 or CYP3A4/5
Medsebojno delovanje z zdravili, ki se presnavljajo preko CYP2D6 ali CYP3A4/5
Some patients required discontinuation of temsirolimus or treatment with corticosteroids and/or antibiotics, while some patients continued treatment without additional intervention.
Pri nekaterih bolnikih je bilo treba temsirolimus ukiniti ali pa jih je bilo treba zdraviti s kortikosteroidi in/ali antibiotiki, medtem ko so drugi bolniki nadaljevali z zdravljenjem brez dodatne intervencije.
Torisel has not been studied in pregnant women, and it must not be used during pregnancy, unless clearly necessary.
Zdravila Torisel pri nosečnicah niso raziskovali in ga v nosečnosti ne smete uporabljati, razen če je to nujno potrebno.
The European Medicines Agency has waived the obligation to submit the results of studies with Torisel in all subsets of the paediatric population in MCL (see section 4.2 on paediatric use).
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Torisel za vse podskupine pediatrične populacije pri MCL (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
It is important that the recommendations in section 4.2 be followed closely.
Pomembno je, da natančno sledimo priporočilom v poglavju 4.2.
In the MCL clinical trial, there was no difference in efficacy in patients with respect to age, sex, race, geographic region, or baseline disease characteristics.
V kliničnem preskušanju MCL ni bilo razlik v učinkovitosti pri bolnikih glede na starost, spol, raso, zemljepisno območje ali izhodiščne značilnosti bolezni.
The starting dose of 175 mg was associated with a significant incidence of adverse events and required dose reductions/delays in the majority of patients.
Začetni odmerek 175 mg je bil povezan s pomembno pogostnostjo pojavljanja neželenih učinkov in je zahteval zmanjšanje/zakasnitev odmerka pri večini bolnikov.
Read all of this leaflet carefully before you are given this medicine because it contains important information for you
Pred začetkom uporabe zdravila natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
The most important side effects you may experience during the treatment with Torisel are listed below.
Najpomembnejši neželeni učinki, ki se lahko pojavijo med zdravljenjem z zdravilom Torisel, so našteti spodaj.
The amount of alcohol in this medicine may impair your ability to drive or alter the effects of other medicines (see sections “Warning and precautions” and “Driving and using machines”).
Količina alkohola v tem zdravilu lahko zmanjša vašo sposobnost vožnje ali spremeni učinke drugih zdravil (glejte poglavji “Opozorila in previdnostni ukrepi” ter “Vpliv na sposobnost upravljanja vozil in strojev”).
b Disease assessment is based on radiographic review by independent radiologists and review of clinical data by independent oncologists.
Ocena bolezni temelji na radiografskem pregledu neodvisnih radiologov in pregledu kliničnih podatkov s strani neodvisnih onkologov.
if you have or have had high cholesterol levels.
- če imate ali ste kdaj imeli zvišane ravni holesterola.
Torisel contains ethanol (alcohol)
Zdravilo Torisel vsebuje etanol (alkohol)
If a patient develops a hypersensitivity reaction during the temsirolimus infusion despite the premedication, the infusion must be stopped and the patient observed for at least 30 to 60 minutes (depending on the severity of the reaction).
Če pri bolniku med infuzijo temsirolimusa kljub premedikaciji pride do preobčutljivostne reakcije, je treba infuzijo prekiniti in bolnika opazovati vsaj 30 do 60 minut (odvisno od resnosti reakcije).
if you are allergic to antihistamines or cannot use antihistamines for other medical reasons.
- če ste alergični na antihistaminike ali iz kakšnega drugega medicinskega razloga ne smete uporabljati antihistaminikov.
Interactions with medicinal products that are P-glycoprotein substrates
Medsebojno delovanje z zdravili, ki so substrati P-glikoproteina
Your doctor will do blood tests to check your liver function and then may decide to lower the dose of Torisel.
Zdravnik bo naročil preiskave krvi, da bi preveril delovanje jeter, in se nato morda odločil za zmanjšanje odmerka zdravila Torisel.
Patients should be monitored early during the infusion and appropriate supportive care should be available.
Bolnike je treba spremljati ob začetku infuzije, na voljo pa mora biti ustrezno podporno zdravljenje.
If the administration set available does not have an in-line filter incorporated, a filter should be added at the end of the set (i.e., an end-filter) before the admixture reaches the vein of the patient.
Če infuzijski sistem, ki je na voljo, nima zaporedno vključenega filtra, morate dodati filter na koncu infuzijskega sistema (tj. končni filter), preden mešanica doseže bolnikovo veno.
b Based on Cox proportional hazard model stratified by prior nephrectomy and region (95% CI are descriptive only).
Na podlagi Coxovega modela proporcionalnega tveganja, stratificiranega po predhodni nefrektomiji in regiji (95% IZ je samo opisnega).
Swelling of the face, lips, tongue, and throat, possibly causing difficulty breathing.
Otekanje obraza, ustnic, jezika in žrela, ki lahko oteži dihanje.
It is recommended that patients be followed closely for occurrence of clinical respiratory symptoms and patients should be advised to report promptly any new or worsening respiratory symptoms.
Bolnike je priporočljivo skrbno spremljati glede kliničnih respiratornih simptomov in jim svetovati, naj čim prej poročajo o poslabšanju ali novih respiratornih simptomih.
The combination of temsirolimus and sunitinib resulted in dose-limiting toxicity.
Kombinacija temsirolimusa in sunitiniba je povzročila toksičnost, ki je omejila odmerek.
Your doctor will monitor your kidney function.
Zdravnik bo spremljal delovanje vaših ledvic.
The use of temsirolimus was associated with increases in serum triglycerides and cholesterol.
Uporaba temsirolimusa je bila povezana z zvišanjem ravni serumskih trigliceridov in holesterola.
Cases of PCP, some with fatal outcomes, have been reported (see section 4.4).
Poročali so o primerih PCP, nekaterih s smrtnim izidom (glejte poglavje 4.4).
What you need to know before you receive Torisel
Kaj morate vedeti, preden boste prejeli zdravilo Torisel
Torisel is for intravenous use only.
Zdravilo Torisel je samo za intravensko uporabo.
The safety and efficacy of temsirolimus in the treatment of advanced RCC were studied in the following two randomised clinical trials:
Varnost in učinkovitost temsirolimusa pri zdravljenju napredovalega RCC so proučevali v naslednjih dveh randomiziranih kliničnih preskušanjih:
In RCC clinical trial 1, 31% of patients treated with temsirolimus were 65 or older.
V kliničnem preskušanju RCC 1 je bilo 31 % bolnikov, zdravljenih s temsirolimusom, starih 65 let ali več.
Therefore, inhibitors of these metabolic pathways are not expected to affect the elimination of temsirolimus.
Zato ni pričakovati, da bi zaviralci teh presnovnih poti vplivali na odstranjevanje temsirolimusa iz telesa.
Lung infection caused by Pneumocystis jiroveci (Pneumocystis jiroveci pneumonia).
Okužba pljuč, ki jo povzroča Pneumocystis jiroveci (pljučnica zaradi Pneumocystis jiroveci).
if you have or have had tumours in your brain or spinal cord, bleeding problems or bruising, or if you are taking medicines which prevent your blood from clotting (such as warfarin and acenocoumarole).
- če imate ali ste kdaj imeli tumorje v možganih ali hrbtenjači, težave s krvavitvami ali podplutbami ali če jemljete zdravila, ki preprečujejo strjevanje krvi (kot sta varfarin ali acenokumarol).
Tell your doctor if you have a drinking problem or consume alcohol (see section “Torisel contains ethanol [alcohol]”).
Zdravniku povejte, če imate težave z alkoholom ali pijete alkohol (glejte poglavje “Zdravilo Torisel vsebuje etanol (alkohol)”).
In rats, these changes were accompanied by a decreased weight of accessory sex organs (epididymides, prostate, seminal vesicles).
Pri podganah je te spremembe spremljala zmanjšana teža pomožnih spolnih organov (obmodkov, prostate, semenjakov).
General inflammatory responses, as indicated by increased fibrinogen and neutrophils, and/or changes in serum protein, were observed in mice, rats, and monkeys, although in some cases these clinical pathology changes were attributed to skin or intestinal inflammation as noted above.
Splošne vnetne odzive, na katere kažejo zvišan fibrinogen in nevtrofilci in/ali spremembe serumskih beljakovin, so opazili pri miših, podganah in opicah, čeprav so v nekaterih primerih te kliničnopatološke spremembe pripisali vnetju kože ali črevesa, kot je opisano zgoraj.
A vaccination may be less effective or the use of certain vaccinations should be avoided during treatment with Torisel.
Cepljenje bo morda manj učinkovito, nekaterih cepljenj pa se morate med zdravljenjem z zdravilom Torisel izogibati.
For intravenous use.
za intravensko uporabo
Different end-filters can be used ranging in filter pore size from 0.2 microns up to 5 microns.
Uporabljate lahko različne končne filtre, pri katerih sega velikost filtrirnih por od 0,2 mikrona do 5 mikronov.
if you have shortness of breath, cough, and/or fever.
- če imate kratko sapo, kašljate in/ali imate vročino.
Torisel will always be prepared and given to you by a doctor or another healthcare professional as an intravenous infusion (into your vein).
Zdravilo Torisel bo vedno pripravil in vam ga dal v obliki intravenske infuzije (v vašo veno) zdravnik ali drug zdravstveni delavec.
Hyperglycaemia/glucose intolerance/diabetes mellitus
Hiperglikemija/intoleranca za glukozo/sladkorna bolezen
Abbreviations: CI = confidence interval; NA = not applicable.
Okrajšave: IZ = interval zaupanja; NA = navedba smiselno ni potrebna.
Torisel is unlikely to influence the ability to drive and use machines.
Ni verjetno, da bi zdravilo Torisel vplivalo na sposobnost vožnje in upravljanja strojev.
if the number of platelet (a type of blood cell that helps to clot blood) has decreased.
- če je število krvnih ploščic (vrsta krvnih celic, ki sodeluje pri strjevanju krvi) zmanjšano.
Patients should be advised to report excessive thirst or any increase in the volume or frequency of urination.
Bolnike je treba opozoriti, naj poročajo o prekomerni žeji ali zvečanju količine ali pogostnosti uriniranja.
In particular, you should inform your doctor or pharmacist if you are taking any of the following:
Še posebej je pomembno, da zdravniku ali farmacevtu poveste, če jemljete kaj od naštetega:
Pharmacokinetic data on temsirolimus and sirolimus are available in patients up to age 79 years.
No voljo so podatki o farmakokinetiki temsirolimusa in sirolimusa pri bolnikih, starih do 79 let.
Opportunistic infections such as PCP should be considered in the differential diagnosis.
Pri diferencialni diagnozi je treba upoštevati tudi oportunistične okužbe, kot je PCP.
See section 4.4 for additional information concerning serious adverse reactions, including appropriate actions to be taken if specific reactions occur.
Za dodatne informacije o resnih neželenih učinkih in ustrezne ukrepe v primeru pojava določenih neželenih učinkov glejte poglavje 4.4.
What Torisel is and what it is used for
Kaj je zdravilo Torisel in za kaj ga uporabljamo
Patients should be advised that treatment with temsirolimus may be associated with an increase in blood glucose levels in diabetic and non-diabetic patients.
Bolnike je treba opozoriti, da je zdravljenje s temsirolimusom lahko povezano z zvečano koncentracijo glukoze v krvi tako pri diabetikih kot nediabetikih.
Administration of corticosteroids may be considered; however, the efficacy of corticosteroid treatment in this setting has not been established.
V poštev pride aplikacija kortikosteroidov, vendar učinkovitost zdravljenja s kortikosteroidi v teh okoliščinah ni bila dokazana.
Torisel must not be used during pregnancy, unless the risk for the embryo is justified by the expected benefit for the mother.
Zdravila Torisel se ne sme uporabljati med nosečnostjo, če tveganja za zarodek ne upravičujejo pričakovane koristi za mater.
if your blood levels of cholesterol and triglycerides have increased.
- če so ravni holesterola in trigliceridov v vaši krvi povečane.
The amount of alcohol in this medicinal product may impair the ability to drive or use machines (see section 4.7).
Količina alkohola v tem zdravilu lahko zmanjša sposobnost vožnje in upravljanja strojev (glejte poglavje 4.7).
Tell your doctor if you experience new or worsening symptoms, or if you are taking or have recently taken medicines that weaken your immune system.
Zdravniku povejte, če se vam pojavijo novi simptomi, če se že obstoječi simptomi poslabšajo ali če jemljete ali ste pred kratkim jemali zdravila, ki oslabijo imunski sistem.
The use of both an in-line and end-filter is not recommended (see sections 6.1 and 6.2).
Uporaba obeh filtrov, zaporedno vključenega in končnega, ni priporočljiva (glejte poglavji 6.1 in 6.2).
Bleeding in the brain
Krvavitve v možganih
Temsirolimus exhibits a polyexponential decline in whole blood concentrations, and distribution is attributable to preferential binding to FKBP-12 in blood cells.
Temsirolimus kaže polieksponencialno zmanjševanje koncentracije v polni krvi, porazdelitev pa lahko pripišemo preferenčni vezavi na FKBP-12 v krvničkah.
The incidence and severity of adverse events is dose-dependent.
Pogostnost in resnost neželenih učinkov sta odvisni od odmerka.
if you are receiving Torisel, you may be at increased risk of heart attack.
- če prejemate zdravilo Torisel, ste lahko izpostavljeni povečanemu tveganju za srčni infarkt.
Patients receiving the starting dose of 175 mg weekly for the treatment of MCL must be followed closely to decide on dose reductions/delays.
Bolnike, ki prejmejo začetni odmerek 175 mg na teden za zdravljenje MCL, je treba skrbno spremljati, da se lahko odločimo glede zmanjšanja/zakasnitve odmerka.
Sulfate or glucuronide conjugates were not detected in the human faecal samples, suggesting that sulfation and glucuronidation do not appear to be major pathways involved in the excretion of temsirolimus.
V vzorcih človeškega blata niso odkrili sulfatnih ali glukuronidnih konjugatov, kar kaže na to, da sulfatacija in glukuronidacija nista pomembni poti, vpleteni v izločanje temsirolimusa.
Your doctor may delay the administration of Torisel until the wound is fully recovered as this medicine could interfere with the healing processes of pre-existing wounds.
Zdravnik bo morda odložil zdravljenje z zdravilom Torisel, dokler se rana popolnoma ne zaceli, saj lahko to zdravilo vpliva na celjenje že obstoječih ran.
Hypersensitivity/infusion reactions
Preobčutljivostne reakcije/reakcije na infuzijo
Investigator's choice therapies included: gemcitabine (intravenous: 22 [41.5%]), fludarabine (intravenous: 12 [22.6%] or oral: 2 [3.8%]), chlorambucil (oral: 3 [5.7%]), cladribine (intravenous: 3 [5.7%]), etoposide (intravenous: 3 [5.7%]), cyclophosphamide (oral: 2 [3.8%]), thalidomide (oral: 2 [3.8%]), vinblastine (intravenous: 2 [3.8%]), alemtuzumab (intravenous: 1 [1.9%]), and lenalidomide (oral: 1 [1.9%]).
Zdravljenje, ki ga je izbral raziskovalec, je vključevalo: gemcitabin (intravensko: 22 [41,5 %]), fludarabin (intravensko: 12 [22,6 %] ali peroralno: 2 [3,8 %]), klorambucil (peroralno: 3 [5,7 %]), kladribin (intravensko: 3 [5,7 %]), etopozid (intravensko: 3 [5,7 %]), ciklofosfamid (peroralno: 2 [3,8 %]), talidomid (peroralno: 2 [3,8 %]), vinblastin (intravensko: 2 [3,8 %]), alemtuzumab (intravensko: 1 [1,9 %]) in lenalidomid (peroralno: 1 [1,9 %]).
It is harmful if you are suffering from alcoholism, and it is to be taken into account in pregnant or breast-feeding women, children and high-risk groups such as patients with liver disease or epilepsy.
Škodljivo je, če trpite za alkoholizmom, vsebnost alkohola pa je treba upoštevati tudi pri nosečnicah ali doječih materah, otrocih in skupinah z velikim tveganjem, kot so bolniki z jetrnimi obolenji ali epilepsijo.
The use of temsirolimus has been associated with abnormal wound healing; therefore, caution should be exercised with the use of temsirolimus in the peri-surgical period.
Uporaba temsirolimusa je bila povezana z nenormalnim celjenjem ran; zato je v perioperativnem obdobju pri uporabi temsirolimusa potrebna previdnost.
It is important that the recommendations in sections 4.2 and 6.6 be followed closely.
Pomembno je, da natančno sledimo priporočilom v poglavjih 4.2 in 6.6.
If you experience any of these during the administration of Torisel, the doctor or nurse will stop the infusion.
Če se vam med prejemanjem zdravila Torisel pojavi karkoli od naštetega, bo zdravnik ali medicinska sestra prekinil dajanje infuzije.
Grapefruit and grapefruit juice may increase blood concentrations of Torisel and should be avoided.
Grenivke in sok grenivk lahko zvečajo koncentracijo zdravila Torisel v krvi in se jim je treba izogibati.
Although phospholipidosis has not been shown to be a risk for patients administered temsirolimus, it is possible that combined administration of temsirolimus with other amphiphilic agents such as amiodarone or statins could result in an increased risk of amphiphilic pulmonary toxicity.
Čeprav niso dokazali, da bi bila fosfolipidoza možna nevarnost za bolnike, zdravljene s temsirolimusom, je možno, da bi kombinirana uporaba temsirolimusa z drugimi amfifilnimi sredstvi, na primer amiodaronom ali statini, lahko povzročila zvečano tveganje amfifilne toksičnosti za pljuča.
High concentrations resulted in complete cell growth inhibition in vitro, whereas inhibition mediated by FKBP-12/temsirolimus complex alone resulted in approximately 50% decrease in cell proliferation.
Velike koncentracije so povzročile popolno zavrtje celične rasti in vitro, medtem ko je zavrtje, ki ga posreduje kompleks FKBP-12/temsirolimus, povzročilo približno 50-odstotno zmanjšanje proliferacije celic.
Because it is recommended that an H1 antihistamine be administered to patients before the start of the intravenous temsirolimus infusion, temsirolimus should be used with caution in patients with known hypersensitivity to the antihistamine or in patients who cannot receive the antihistamine for other medical reasons.
Ker je priporočljivo bolnikom pred začetkom intravenske infuzije temsirolimusa dati antihistaminik H1, je treba pri bolnikih z znano preobčutljivostjo na antihistaminike ali pri bolnikih, ki iz drugih medicinskih razlogov ne smejo prejeti antihistaminika, temsirolimus uporabljati previdno.
Mean half-lives of temsirolimus and sirolimus were 17.7 hours and 73.3 hours, respectively.
Povprečna razpolovna doba temsirolimusa je bila 17,7 ure, sirolimusa pa 73,3 ure.
Temsirolimus elimination by the kidneys is negligible; studies in patients with varying renal impairment have not been conducted (see sections 4.2 and 5.2).
Izločanje temsirolimusa preko ledvic je zanemarljivo; študij pri bolnikih z različnimi ledvičnimi okvarami niso izvedli (glejte poglavji 4.2 in 5.2).
Some medicines can interfere with the breakdown or metabolism of Torisel and therefore dose adjustment of Torisel may be required.
Nekatera zdravila lahko vplivajo na razgradnjo ali presnovo zdravila Torisel in zato bo morda potrebna prilagoditev odmerka zdravila Torisel.
Some patients were asymptomatic or had minimal symptoms with pneumonitis detected on computed tomography scan or chest radiograph.
Nekateri bolniki so bili asimptomatski ali pa so imeli neznatne simptome in so jim pljučnico odkrili pri računalniški tomografiji ali rentgenskem slikanju prsnega koša.
Temsirolimus dose modifications based on weekly ANC and platelet counts ANC
Spremembe odmerka temsirolimusa glede na tedensko ANC in trombocite ANC
Phospholipidosis has not been observed in mice or monkeys treated with temsirolimus, nor has it been documented in patients treated with temsirolimus.
Fosfolipidoze niso opazili pri miših in opicah, ki so jim dajali temsirolimus, prav tako je niso dokumentirali pri bolnikih, zdravljenih s temsirolimusom.
if you have or have had eye problems like cataracts.
- če imate ali ste kdaj imeli težave z očmi, kot so katarakte.
For subjects with neuroblastoma, the objective response rate was 5.3% (95% CI: 0.1%, 26.0%).
Pri bolnikih z nevroblastomom je objektivni odziv na zdravljenje znašal 5,3 % (95 % IZ: 0,1 %; 26,0 %).
Due to the unknown risk related to potential exposure during early pregnancy, women of childbearing potential must be advised not to become pregnant while using Torisel.
Zaradi neznanega tveganja, povezanega z možno izpostavljenostjo ploda v zgodnji nosečnosti, je treba ženskam v rodni dobi svetovati, naj med zdravljenjem z zdravilom Torisel ne zanosijo.